Neoadjuvant Immunochemotherapy for Lung Cancer
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.
Lung Cancer
DRUG: Neoadjuvant immunochemotherapy
Progression-free survival (PFS), Progression-free defined as status of recurrence of lung cancer, 2017-2023|Overall survival (OS), Overall defined as the living status, alive or dead, 2017-2023
We retrospectively analyzed lung cancer patients who had NAICT and surgery in the Department of Thoracic Surgery, Zhongshan Hospital. NAICT was defined as chemotherapy that included at one application of PD-1 inhibitor.